The emerging role of T cell cytokines in non-small cell lung cancer

Cytokine and Growth Factor Reviews

Volumn 23, Issue 6, 2012, Pages 315-322

  Neurath, Markus F ^a   Finotto, Susetta ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Cytokines; Lung cancer; Regulatory T cells; T cells; Th1; Th17

Indexed keywords

CD27 ANTIGEN; CD28 ANTIGEN; CD69 ANTIGEN; CRIZOTINIB; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; GAMMA INTERFERON; GEFITINIB; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 22; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; RETINOID RELATED ORPHAN RECEPTOR ALPHA; STAT1 PROTEIN; STAT6 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR;

CANCER INHIBITION; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CYTOKINE PRODUCTION; DRUG EFFICACY; HUMAN; IMMUNOREGULATION; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTIC INFILTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SHORT SURVEY; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR PROMOTION;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CYTOKINES; HUMANS; INFLAMMATION; LUNG; T-LYMPHOCYTES;

EID: 84869861913     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2012.08.009     Document Type: Short Survey

References (105)

1. Reedy J. Galen on cancer and related diseases. Clio Medica 1975, 10:227-238.
2. Retief F.P., Cilliers L. Breast cancer in antiquity. South African Medical Journal=Suid-Afrikaanse tydskrif vir geneeskunde 2011, 101:513-515.
3. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545.
4. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
5. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
6. Kerkar S.P., Restifo N.P. Cellular constituents of immune escape within the tumor microenvironment. Cancer Research 2012, 72:3125-3130.
7. Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. New England Journal of Medicine 1986, 315:1650-1659.
8. Milara J., Cortijo J. Tobacco, inflammation, and respiratory tract cancer. Current Pharmaceutical Design 2012, 18:3901-3938.
9. Loganathan R.S., Stover D.E., Shi W., Venkatraman E. Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer. Chest 2006, 129:1305-1312.
10. Zheng W., Blot W.J., Liao M.L., Wang Z.X., Levin L.I., Zhao J.J., et al. Lung cancer and prior tuberculosis infection in Shanghai. British Journal of Cancer 1987, 56:501-504.
11. O'Callaghan D.S., O'Donnell D., O'Connell F., O'Byrne K.J. The role of inflammation in the pathogenesis of non-small cell lung cancer. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 2010, 5:2024-2036.
12. Greenlee R.T., Hill-Harmon M.B., Murray T., Thun M. Cancer statistics, 2001. CA: A Cancer Journal for Clinicians 2001, 51:15-36.
13. Aggarwal C., Langer C.J. Older age, poor performance status and major comorbidities: how to treat high-risk patients with advanced nonsmall cell lung cancer. Current Opinion in Oncology 2012, 24:130-136.
14. Travis W.D., Travis L.B., Devesa S.S. Lung cancer. Cancer 1995, 75:191-202.
15. Saintigny P., Burger J.A. Recent advances in non-small cell lung cancer biology and clinical management. Discovery Medicine 2012, 13:287-297.
16. Swartz M.A., Iida N., Roberts E.W., Sangaletti S., Wong M.H., Yull F.E., et al. Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Research 2012, 72:2473-2480.
17. Nelson D., Ganss R. Tumor growth or regression: powered by inflammation. Journal of Leukocyte Biology 2006, 80:685-690.
18. Marc M.M., Korosec P., Kern I., Sok M., Ihan A., Kosnik M. Lung tissue and tumour-infiltrating T lymphocytes in patients with non-small cell lung carcinoma and chronic obstructive pulmonary disease (COPD): moderate/severe versus mild stage of COPD. Scandinavian Journal of Immunology 2007, 66:694-702.
19. Tormanen-Napankangas U., Soini Y., Paakko P. High number of tumour-infiltrating lymphocytes is associated with apoptosis in non-small cell lung carcinoma. APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica 2001, 109:525-532.
20. Ortegel J.W., Staren E.D., Faber L.P., Warren W.H., Braun D.P. Cytokine biosynthesis by tumor-infiltrating T lymphocytes from human non-small-cell lung carcinoma. Cancer Immunology, Immunotherapy: CII 2000, 48:627-634.
21. Petersen R.P., Campa M.J., Sperlazza J., Conlon D., Joshi M.B., Harpole D.H., et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006, 107:2866-2872.
22. Aoki M., Saikawa Y., Hosokawa S., Fukuda K., Kumai K., Kubota T., et al. A novel human monoclonal antibody derived from tumor-infiltrating lymphocytes in lung cancer inhibits cancer cell growth with morphological changes. Anticancer Research 2005, 25:3791-3798.
23. Yannelli J.R., Hirscowitz E., Wroblewski J.M. Growth and functional reactivity of lymphocytes obtained from three anatomic compartments in patients with non-small-cell lung cancer (NSCLC). Cancer Biotherapy and Radiopharmaceuticals 2003, 18:735-749.
24. Kataki A., Scheid P., Piet M., Marie B., Martinet N., Martinet Y., et al. Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. The Journal of Laboratory and Clinical Medicine 2002, 140:320-328.
25. Semino C., Ferlazzo G., Ratto G.B., Melioli G. Analysis of HLA-class-I specific natural killer cell receptors expressed on T lymphocytes infiltrating non-small-cell lung cancer. Lung Cancer 2001, 34:395-405.
26. Yoshino I., Yano T., Murata M., Miyamoto M., Ishida T., Sugimachi K., et al. Phenotypes of lymphocytes infiltrating non-small cell lung cancer tissues and its variation with histological types of cancer. Lung Cancer 1993, 10:13-19.
27. Imahayashi S., So T., Sugaya M., Yasuda M., Eifuku R., Takenoyama M., et al. Establishment of an immortalized T-cell line from lung cancer tissue: phenotypic and functional analyses. International Journal of Clinical Oncology/Japan Society of Clinical Oncology 2002, 7:38-44.
28. Arens R., Schoenberger S.P. Plasticity in programming of effector and memory CD8 T-cell formation. Immunological Reviews 2010, 235:190-205.
29. Riemann D., Wenzel K., Schulz T., Hofmann S., Neef H., Lautenschlager C., et al. Phenotypic analysis of T lymphocytes isolated from non-small-cell lung cancer. International Archives of Allergy and Immunology 1997, 114:38-45.
30. Johnson S.K., Kerr K.M., Chapman A.D., Kennedy M.M., King G., Cockburn J.S., et al. Immune cell infiltrates and prognosis in primary carcinoma of the lung. Lung Cancer 2000, 27:27-35.
31. Ruffini E., Asioli S., Filosso P.L., Lyberis P., Bruna M.C., Macri L., et al. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. The Annals of Thoracic Surgery 2009, 87:365-371. [discussion 371-362].
32. Horne Z.D., Jack R., Gray Z.T., Siegfried J.M., Wilson D.O., Yousem S.A., et al. Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer. The Journal of Surgical Research 2011, 171:1-5.
33. Kilic A., Landreneau R.J., Luketich J.D., Pennathur A., Schuchert M.J. Density of tumor-infiltrating lymphocytes correlates with disease recurrence and survival in patients with large non-small-cell lung cancer tumors. The Journal of Surgical Research 2011, 167:207-210.
34. Dieu-Nosjean M.C., Antoine M., Danel C., Heudes D., Wislez M., Poulot V., et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. Journal of Clinical Oncology 2008, 26:4410-4417.
35. Turtle C.J., Riddell S.R. Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy. Current Opinion in Immunology 2011, 23:299-305.
36. Groeper C., Gambazzi F., Zajac P., Bubendorf L., Adamina M., Rosenthal R., et al. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer. International Journal of Cancer Journal International du Cancer 2007, 120:337-343.
37. Kawai O., Ishii G., Kubota K., Murata Y., Naito Y., Mizuno T., et al. Predominant infiltration of macrophages and CD8(+) T cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 2008, 113:1387-1395.
38. Al-Shibli K.I., Donnem T., Al-Saad S., Persson M., Bremnes R.M., Busund L.T. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2008, 14:5220-5227.
39. Hiraoka K., Miyamoto M., Cho Y., Suzuoki M., Oshikiri T., Nakakubo Y., et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. British Journal of Cancer 2006, 94:275-280.
40. Wakabayashi O., Yamazaki K., Oizumi S., Hommura F., Kinoshita I., Ogura S., et al. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Science 2003, 94:1003-1009.
41. Trojan A., Urosevic M., Dummer R., Giger R., Weder W., Stahel R.A. Immune activation status of CD8+ T cells infiltrating non-small cell lung cancer. Lung Cancer 2004, 44:143-147.
42. Liu H., Zhang T., Ye J., Li H., Huang J., Li X., et al. Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer. Cancer Immunology, Immunotherapy: CII 2012, [Epub ahead of print].
43. Ito N., Suzuki Y., Taniguchi Y., Ishiguro K., Nakamura H., Ohgi S. Prognostic significance of T helper 1 and 2 and T cytotoxic 1 and 2 cells in patients with non-small cell lung cancer. Anticancer Research 2005, 25:2027-2031.
44. Ortegel J.W., Staren E.D., Faber L.P., Warren W.H., Braun D.P. Modulation of tumor-infiltrating lymphocyte cytolytic activity against human non-small cell lung cancer. Lung Cancer 2002, 36:17-25.
45. Asselin-Paturel C., Echchakir H., Carayol G., Gay F., Opolon P., Grunenwald D., et al. Quantitative analysis of Th1, Th2 and TGF-beta1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients. International Journal of Cancer Journal International du Cancer 1998, 77:7-12.
46. Gough D.J., Levy D.E., Johnstone R.W., Clarke C.J. IFNgamma signaling-does it mean JAK-STAT?. Cytokine and Growth Factor Reviews 2008, 19:383-394.
47. Young H.A., Bream J.H. IFN-gamma: recent advances in understanding regulation of expression, biological functions, and clinical applications. Current Topics in Microbiology and Immunology 2007, 316:97-117.
48. El Hage F., Vergnon I., Grunenwald D., Soria J.C., Chouaib S., Mami-Chouaib F. Generation of diverse mutated tumor antigen-specific cytotoxic T lymphocytes in a lung cancer patient with long survival. Oncology Reports 2005, 14:763-769.
49. Barth R.J., Mule J.J., Spiess P.J., Rosenberg S.A. Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. Journal of Experimental Medicine 1991, 173:647-658.
50. Weynants P., Wauters P., Coulie P.G., Van den Eynde B., Symann M., Boon T. Cytolytic response of human T cells against allogeneic small cell lung carcinoma treated with interferon gamma. Cancer Immunology, Immunotherapy: CII 1988, 27:228-232.
51. Swisher S.G., Kiertscher S.M., Golub S.H., Holmes E.C., Roth M.D. Pulmonary macrophages suppress the proliferation and cytotoxicity of tumor-infiltrating lymphocytes. American Journal of Respiratory Cell and Molecular Biology 1993, 8:486-492.
52. Mucida D., Cheroutre H. The many face-lifts of CD4 T helper cells. Advances in Immunology 2010, 107:139-152.
53. Littman D.R., Rudensky A.Y. Th17 and regulatory T cells in mediating and restraining inflammation. Cell 2010, 140:845-858.
54. Finotto S., Neurath M.F., Glickman J.N., Qin S., Lehr H.A., Green F.H., et al. Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science 2002, 295:336-338.
55. Finotto S., De Sanctis G.T., Lehr H.A., Herz U., Buerke M., Schipp M., et al. Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression. Journal of Experimental Medicine 2001, 193:1247-1260.
56. Mowen K.A., Glimcher L.H. Signaling pathways in Th2 development. Immunological Reviews 2004, 202:203-222.
57. Neurath M.F., Finotto S., Glimcher L.H. The role of Th1/Th2 polarization in mucosal immunity. Nature Medicine 2002, 8:567-573.
58. Leppkes M., Becker C., Ivanov I.I., Hirth S., Wirtz S., Neufert C., et al. RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology 2009, 136:257-267.
59. Wing J.B., Sakaguchi S. Multiple treg suppressive modules and their adaptability. Frontiers in Immunology 2012, 3:178.
60. Ito N., Nakamura H., Tanaka Y., Ohgi S. Lung carcinoma: analysis of T helper type 1 and 2 cells and T cytotoxic type 1 and 2 cells by intracellular cytokine detection with flow cytometry. Cancer 1999, 85:2359-2367.
61. Vitolo D., Ciocci L., Ferrauti P., Tiboni F., Cicerone E., Gallo A., et al. Interleukin-12-related cytokine gene expression in carcinomas of the breast, lung, and larynx: a study at tissue level. Cancer Detection and Prevention 2000, 24:422-434.
62. Echchakir H., Asselin-Paturel C., Dorothee G., Vergnon I., Grunenwald D., Chouaib S., et al. Analysis of T-cell-receptor beta-chain-gene usage in peripheral-blood and tumor-infiltrating lymphocytes from human non-small-cell lung carcinomas. International Journal of Cancer Journal International du Cancer 1999, 81:205-213.
63. Melioli G., Ratto G., Guastella M., Meta M., Biassoni R., Semino C., et al. Isolation and in vitro expansion of lymphocytes infiltrating non-small cell lung carcinoma: functional and molecular characterisation for their use in adoptive immunotherapy. European Journal of Cancer 1994, 30A:97-102.
64. Nishino R., Takano A., Oshita H., Ishikawa N., Akiyama H., Ito H., et al. Identification of Epstein-Barr virus-induced gene 3 as a novel serum and tissue biomarker and a therapeutic target for lung cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2011, 17:6272-6286.
65. Reppert S., Boross I., Koslowski M., Tureci O., Koch S., Lehr H.A., et al. A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer. Nature Communications 2011, 2:600.
66. Ito N., Nakamura H., Metsugi H., Ohgi S. Dissociation between T helper type 1 and type 2 differentiation and cytokine production in tumor-infiltrating lymphocytes in patients with lung cancer. Surgery Today 2001, 31:390-394.
67. Patel S., Vetale S., Teli P., Mistry R., Chiplunkar S. IL-10 production in non-small cell lung carcinoma patients is regulated by ERK, P38 and COX-2. Journal of Cellular and Molecular Medicine 2012, 16:531-544.
68. Lazarevic V., Chen X., Shim J.H., Hwang E.S., Jang E., Bolm A.N., et al. T-bet represses T(H)17 differentiation by preventing Runx1-mediated activation of the gene encoding RORgammat. Nature Immunology 2011, 12:96-104.
69. Foukas P.G., Tsilivakos V., Zacharatos P., Mariatos G., Moschos S., Syrianou A., et al. Expression of HLA-DR is reduced in tumor infiltrating immune cells (TIICS) and regional lymph nodes of non-small-cell lung carcinomas. A putative mechanism of tumor-induced immunosuppression?. Anticancer Research 2001, 21:2609-2615.
70. Parekh K., Ramachandran S., Cooper J., Bigner D., Patterson A., Mohanakumar T. Tenascin-C, over expressed in lung cancer down regulates effector functions of tumor infiltrating lymphocytes. Lung Cancer 2005, 47:17-29.
71. Huang M., Wang J., Lee P., Sharma S., Mao J.T., Meissner H., et al. Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Research 1995, 55:3847-3853.
72. Asselin-Paturel C., Megherat S., Vergnon I., Echchakir H., Dorothee G., Blesson S., et al. Differential effect of high doses versus low doses of interleukin-12 on the adoptive transfer of human specific cytotoxic T lymphocyte in autologous lung tumors engrafted into severe combined immunodeficiency disease-nonobese diabetic mice: relation with interleukin-10 induction. Cancer 2001, 91:113-122.
73. De Vita F., Orditura M., Galizia G., Romano C., Roscigno A., Lieto E., et al. Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest 2000, 117:365-373.
74. Fantini M.C., Becker C., Monteleone G., Pallone F., Galle P.R., Neurath M.F. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. Journal of Immunology 2004, 172:5149-5153.
75. Chen W., Wahl S.M. TGF-beta: the missing link in CD4+CD25+ regulatory T cell-mediated immunosuppression. Cytokine and Growth Factor Reviews 2003, 14:85-89.
76. Chen W., Jin W., Hardegen N., Lei K.J., Li L., Marinos N., et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. Journal of Experimental Medicine 2003, 198:1875-1886.
77. Ni X.Y., Sui H.X., Liu Y., Ke S.Z., Wang Y.N., Gao F.G. TGF-beta of lung cancer microenvironment upregulates B7H1 and GITRL expression in dendritic cells and is associated with regulatory T cell generation. Oncology Reports 2012, 28:615-621.
78. Woo E.Y., Chu C.S., Goletz T.J., Schlienger K., Yeh H., Coukos G., et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Research 2001, 61:4766-4772.
79. Woo E.Y., Yeh H., Chu C.S., Schlienger K., Carroll R.G., Riley J.L., et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. Journal of Immunology 2002, 168:4272-4276.
80. Sharma S., Yang S.C., Zhu L., Reckamp K., Gardner B., Baratelli F., et al. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+CD25+ T regulatory cell activities in lung cancer. Cancer Research 2005, 65:5211-5220.
81. de Jong E., Suddason T., Lord G.M. Translational mini-review series on Th17 cells: development of mouse and human T helper 17 cells. Clinical and Experimental Immunology 2010, 159:148-158.
82. Crome S.Q., Wang A.Y., Levings M.K. Translational mini-review series on Th17 cells: function and regulation of human T helper 17 cells in health and disease. Clinical and Experimental Immunology 2010, 159:109-119.
83. Lazarevic V., Glimcher L.H. T-bet in disease. Nature Immunology 2011, 12:597-606.
84. Moseley T.A., Haudenschild D.R., Rose L., Reddi A.H. Interleukin-17 family and IL-17 receptors. Cytokine and Growth Factor Reviews 2003, 14:155-174.
85. Li Y., Cao Z.Y., Sun B., Wang G.Y., Fu Z., Liu Y.M., et al. Effects of IL-17A on the occurrence of lung adenocarcinoma. Cancer Biology and Therapy 2011, 12:610-616.
86. Kirshberg S., Izhar U., Amir G., Demma J., Vernea F., Beider K., et al. Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression. PLoS ONE 2011, 6:e24856.
87. Ye Z.J., Zhou Q., Zhang J.C., Li X., Wu C., Qin S.M., et al. CD39+ regulatory T cells suppress generation and differentiation of Th17 cells in human malignant pleural effusion via a lap-dependent mechanism. Respiratory Research 2011, 12:77.
88. Carmi Y., Rinott G., Dotan S., Elkabets M., Rider P., Voronov E., et al. Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis. Journal of Immunology 2011, 186:3462-3471.
89. Doganci A., Eigenbrod T., Krug N., De Sanctis G.T., Hausding M., Erpenbeck V.J., et al. The IL-6R alpha chain controls lung CD4+CD25+ treg development and function during allergic airway inflammation in vivo. Journal of Clinical Investigation 2005, 115:313-325.
90. Muranski P., Boni A., Antony P.A., Cassard L., Irvine K.R., Kaiser A., et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008, 112:362-373.
91. Ankathatti Munegowda M., Deng Y., Mulligan S.J., Xiang J. Th17 and Th17-stimulated CD8(+) T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunity. Cancer Immunology, Immunotherapy: CII 2011, 60:1473-1484.
92. Iida T., Iwahashi M., Katsuda M., Ishida K., Nakamori M., Nakamura M., et al. Tumor-infiltrating CD4+ Th17 cells produce IL-17 in tumor microenvironment and promote tumor progression in human gastric cancer. Oncology Reports 2011, 25:1271-1277.
93. Chae W.J., Gibson T.F., Zelterman D., Hao L., Henegariu O., Bothwell A.L. Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:5540-5544.
94. Charles K.A., Kulbe H., Soper R., Escorcio-Correia M., Lawrence T., Schultheis A., et al. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. Journal of Clinical Investigation 2009, 119:3011-3023.
95. Reppert S., Koch S., Finotto S. IL-17a is a central regulator of lung tumor growth. OncoImmunology 2012, 1:1-3.
96. Liu L., Ge D., Ma L., Mei J., Liu S., Zhang Q., et al. Interleukin-17 and prostaglandin E2 are involved in formation of an M2 macrophage-dominant microenvironment in lung cancer. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 2012, 7:1091-1100.
97. Camporeale A., Poli V. IL-6, IL-17 and STAT3: a holy trinity in auto-immunity?. Frontiers in Bioscience: A Journal and Virtual Library of Medicine 2012, 17:2306-2326.
98. Lavecchia A., Di Giovanni C., Novellino E. STAT-3 inhibitors: state of the art and new horizons for cancer treatment. Current Medicinal Chemistry 2011, 18:2359-2375.
99. Johnston P.A., Grandis J.R. STAT3 signaling: anticancer strategies and challenges. Molecular Interventions 2011, 11:18-26.
100. Neurath M.F., Finotto S. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine and Growth Factor Reviews 2011, 22:83-89.
101. Numasaki M., Watanabe M., Suzuki T., Takahashi H., Nakamura A., McAllister F., et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. Journal of Immunology 2005, 175:6177-6189.
102. Chen X., Xie Q., Cheng X., Diao X., Cheng Y., Liu J., et al. Role of interleukin-17 in lymphangiogenesis in non-small-cell lung cancer: enhanced production of vascular endothelial growth factor C in non-small-cell lung carcinoma cells. Cancer Science 2010, 101:2384-2390.
103. Chen X., Wan J., Liu J., Xie W., Diao X., Xu J., et al. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer 2010, 69:348-354.
104. Zhang W., Chen Y., Wei H., Zheng C., Sun R., Zhang J., et al. Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2008, 14:6432-6439.
105. Maxeiner J.H., Karwot R., Sauer K., Scholtes P., Boross I., Koslowski M., et al. A key regulatory role of the transcription factor NFATc2 in bronchial adenocarcinoma via CD8+ T lymphocytes. Cancer Research 2009, 69:3069-3076.